Tiagabine in anxiety disorders

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 14, 2006, Pages 1977-1987

  Schwartz, Thomas L ^a   Nihalani, Nikhil ^b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Anxiety; GABA; Selective GABA reuptake inhibitor; SGRI; Tiagabine

Indexed keywords

4 AMINOBUTYRIC ACID; ALPRAZOLAM; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; DIAZEPAM; GABAPENTIN; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; VALPROIC ACID; VENLAFAXINE; VIGABATRIN;

ANOREXIA; ANXIETY DISORDER; ARTICLE; BODY WEIGHT DISORDER; CASE STUDY; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; GABAERGIC TRANSMISSION; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; INSOMNIA; MIXED ANXIETY AND DEPRESSION; NAUSEA; NEUROTRANSMISSION; NONHUMAN; OPEN STUDY; PANIC; POSTTRAUMATIC STRESS DISORDER; PSYCHOTHERAPY; SEIZURE; SEXUAL DYSFUNCTION; SOCIAL PHOBIA; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; TABLET FORMULATION; TRANQUILIZING ACTIVITY; UNITED STATES; WEIGHT GAIN; XEROSTOMIA;

ANXIETY DISORDERS; EXPERT TESTIMONY; FEMALE; GABA AGONISTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; NIPECOTIC ACIDS; RANDOMIZED CONTROLLED TRIALS; STRESS DISORDERS, POST-TRAUMATIC;

EID: 33749332326     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.14.1977     Document Type: Article

References (50)

1. GRANT BF, STINSON FS, DAWSON DA et al.: Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch. Gen. Psychiatry (2004) 61:807-816.
2. KESSLER RC, CHIU WT, DEMLER O, MERIKANGAS KR, WALTERS EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry (2005) 62:617-627.
3. KESSLER RC, MCGONAGLE KA, ZHAO S et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry (1994) 51:8-19.
4. KESSLER RC, BERGLUND P, DEMLER O, JIN R, MERIKANGAS KR, WALTERS EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry (2005) 62:593-602.
5. LYDIARD RB: The role of GABA in anxiety disorders. J. Clin. Psychiatry (2003) 64(Suppl. 3):21-27.
6. NEMEROFF CB: The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol. Bull. (2003) 37:133-146.
7. GODDARD AW, MASON GF, ALMAI A et al.: Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch. Gen. Psychiatry (2001) 58:556-561.
8. CRESTANI F, LOREZ M, BAER K et al.: Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues. Nat. Neurosci. (1999) 2:833-839.
9. CHANDRA D, KORPI ER, MIRALLES CP, DE BLAS AL, HOMANICS GE: GABAA receptor gamma 2 subunit knockdown mice have enhanced anxiety-like behavior but unaltered hypnotic response to benzodiazepines. BMC. Neurosci. (2005) 6:30.
10. SCHWARTZ TL, NIHALANI N, SIMIONESCU M, HOPKINS G: History repeats itself: pharmacodynamic trends in the treatment of anxiety disorders. Curr. Pharm. Des. (2005) 11:255-263.
11. UHLENHUTH EH, BALTER MB, BAN TA, YANG K: International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997. Depress. Anxiety (1999) 9:107-116.
12. VAN AMERINGEN M, MANCINI C, PIPE B, BENNETT M: Atntiepileptic drugs in the treatment of anxiety disorders: role in therapy. Drugs (2004) 64:2199-2220.
13. STAHL SM, GRADY MM, MORET C, BRILEY M: SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS. Spectr. (2005) 10:732-747.
14. PANDE AC, DAVIDSON JR, JEFFERSON JW et al.: Treatment of social phobia with gabapentin: a placebo-controlled study. J. Clin. Psychopharmacol. (1999) 19:341-348.
15. PANDE AC, FELTNER DE, JEFFERSON JW et al.: Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J. Clin. Psychopharmacol. (2004) 24:141-149.
16. STAHL SM: Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABA. J. Clin. Psychiatry (2004) 65:291-292.
17. BORDEN LA, MURALI DHAR TG, SMITH KE, WEINSHANK RL, BRANCHEK TA, GLUCHOWSKI C: Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur. J. Pharmacol. (1994) 269:219-224.
18. FINK-JENSEN A, SUZDAK PD, SWEDBERG MD, JUDGE ME, HANSEN L, NIELSEN PG: The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur. J. Pharmacol. (1992) 220:197-201.
19. SUZDAK PD, JANSEN JA: A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia (1995) 36:612-626.
20. SCHMITT U, HIEMKE C: Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. Behav. Pharmacol. (1999) 10:131-137.
21. SCHMITT U, LUDDENS H, HIEMKE C: Behavioral effects of GABA(A) receptor stimulation and GABA-transporter inhibition. Pharmacol. Biochem. Behav. (2000) 65:351-356.
22. ZWANZGER P, ESER D, PADBERG F et al.: Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depress. Anxiety. (2003) 18:140-143.
23. ZWANZGER P, RUPPRECHT R: Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J. Psychiatry Neurosci. (2005) 30:167-175.
24. CRANE D: Tiagabine for the treatment of anxiety. Depress. Anxiety. (2003) 18:51-52.
25. ROSENTHAL M: Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J. Clin. Psychiatry (2003) 64:1245-1249.
26. POLLACK MH, ROY BYRNE PP, VAN AMERINGEN M et al.: The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J. Clin. Psychiatry (2005) 66:1401-1408.
27. SCHALLER JL, THOMAS J, RAWLINGS D: Low-dose tiagabine effectiveness in anxiety disorders. MedGenMed. (2004) 6:8.
28. TAYLOR FB: Tiagabine for postanumatic stress disorde: a case series of 7 women. J. Clin. Psychiatry (2003) 64:1421-1425.
29. CONNOR KM, DAVIDSON JR, WEISLER RH, ZHANG W, ABRAHAM K: Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology (2006) 184:21-25.
30. BERIGAN T: Treatment of posttraumatic stress disorder with tiagabine [letter]. Can. J. Psychiatry (2002) 47:788.
31. ZWANZGER P, BAGHAI TC, SCHULE C et al.: Tiagabine improves panic and agoraphobia in panic disorder patients. J. Clin. Psychiatry (2001) 62:656-657.
32. NINAN PT, PAPP L, DUNLOP BW. Relapse prevention study of tiagabine in patients with social anxiety disorder. Poster presented at the 158th American Psychiatric Association Annual Meeting. Atlanta (GA) USA (May 21 - 26, 2005).
33. SCHWARTZ TL: The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol. Bull. (2002) 36:53-57.
34. CARPENTER LL, SCHECTER JM, TYRKA AR et al: Open-label tiagabine monotherapy for major depressive disorder with anxiety. J. Clin. Psychiatry (2006) 67:66-71.
35. SCHWARTZ TL, AZHAR N, HUSAIN J et al.: An open-label study of tiagabine as augmentation therapy for anxiety. Ann. Clin. Psychiatry (2005) 17:167-172.
36. KHAN A, SCHWARTZ TL. Augmentation of SSRI therapy for CAD with tiagabine. Poster presented at the 157th American Psychiatric Association Annual Meeting. New York (NY) USA (May 1 - 6, 2004).
37. FLOWERS CM, RACOOSIN JA, KORTEPETER C: Seizure activity and off-label use of tiagabine. N. Engl. J. Med. (2006) 354:773-774.
38. SCHWARTZ TL, KANG D, KUMARESAN H, CHILTON M, BERTONE F: An open-label study to evaluate switching from an SSRI or SNRI to tiagabine to alleviate antidepressant-induced sexual dysfunction in generalized anxiety disorder. Ann. Clin. Psychiatry (2006) In press.
39. MONTEJO AL, LLORCA G, IZQUIERDO JA, RICO-VILLADEMOROS F: Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J. Clin. Psychiatry (2001) 62(Suppl. 3):10-21.
40. ASHTON H, YOUNG AH: GABA-ergic drugs: exit stage left, enter stage right. J Psychopharmacol. (2003) 17:174-178.
41. SUTTON KG, MARTIN DJ, PINNOCK RD, LEE K, SCOTT RH: Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones. Br. J. Pharmacol. (2002) 135:257-265.
42. MCCLELLAND D, EVANS RM, BARKWORTH L, MARTIN DJ, SCOTT RH: A study comparing the actions of gabapentin and pregabahn on the electrophysiological properties of cultured DRG neurones from neonatal rats. BMC. Pharmacol. (2004) 4:14.
43. SANKAR R, DERDIARIAN AT: Vigabatrin. CNS. Drug. Reviews. (1998) 4:260-274.
44. TRINGALI G, AUBRY JM, MOSCIANESE K et al.: Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission. J. Psychiatry Neurosci. (2004) 29:459-466.
45. ROMEO E, STROHLE A, SPALLETTA G et al.: Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry (1998) 155:910-913.
46. GRIFFIN LD, MELLON SH: Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl. Acad. Sci. USA (1999) 96:13512-13517.
47. STROHLE A, ROMEO E, DI MF et al: GABA(A) receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am. J. Psychiatry (2002) 159:145-147.
48. STAHL SM: Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents. J. Clin. Psychiatry (2002) 63:854-855.
49. GODDARD AW, BROUETTE T, ALMAI A, JETTY P, WOODS SW, CHARNEY D: Early coadministration of clonazepam with sertraline for panic disorder. Arch. Gen. Psychiatry (2001) 58:681-686.
50. SEEDAT S, STEIN MB: Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J. Clin. Psychiatry (2004) 65:244-248.